Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study

Table 3 Insulin resistance change in 26 active rheumatoid arthritis patients exposed to biologics by tofacitinib therapy

Group	Before	After	P value1
All (n = 26)
DAS28	5.265 ± 0.547 (4.54-6.74)	3.051 ± 0.516 (2.11-3.99)	< 0.001
Decrease in DAS28		2.214 ± 0.688 (1.08-3.49)
HOMA-IR	2.548 ± 0.925 (1.33-4.75)	2.251 ± 1.067 (0.85-4.55)	0.016
QUICKI	0.3358 ± 0.0177 (0.305-0.366)	0.3446 ± 0.0242 (0.305-0.394)	0.016
High IR (n = 19)
DAS28	5.316 ± 0.807 (4.63-6.74)	3.070 ± 0.466 (2.42-3.90)	< 0.001
Decrease in DAS28		2.246 ± 0.672 (1.08-3.49)
HOMA-IR	2.924 ± 0.790 (2.10-4.75)	2.545 ± 1.080 (1.05-4.55)	0.018
QUICKI	0.3273 ± 0.0117 (0.305-0.341)	0.3372 ± 0.0214 (0.305-0.380)	0.008
Low IR (n = 7)
DAS28	5.124 ± 0.332 (4.54-5.48)	3.000 ± 0.672 (2.11-3.99)	0.016
Decrease in DAS28		2.124 ± 0.778 (1.25-3.33)
HOMA-IR	1.527 ± 0.159 (1.33-1.77)	1.453± 0.478 (0.85-2.18)	0.781
QUICKI	0.3589 ± 0.0059 (0.350-0.366)	0.3648 ± 0.0204 (0.340-0.394)	0.813

¹Before vs after TOF therapy.

HOMA-IR: Homeostatic model assessment-insulin resistance; QUICKI: Quantitative Insulin Sensitivity Check Index; TOF: Tofacitinib; DAS28: Disease Activity Score 28.